Tang Z Y
Liver Cancer Institute and Zhong Shan Hospital, Shanghai Medical University, Shanghai, PR China.
Digestion. 1998 Aug;59(5):556-62. doi: 10.1159/000007531.
Treatment of hepatocellular carcinoma (HCC) remains a critical issue particularly in the endemic areas. This paper summarizes the literature in the recent 4 years and the author's data. Substantial progress has been found in the treatment of HCC during the recent decades, which was mainly a result of advances in medical imaging, aggressive surgical approach, regional cancer therapies and multidisciplinary approach. Surgical approaches that resulted in significant prolonged survival included: resection (particularly small HCC resection), re-resection for subclinical recurrence, cytoreduction and sequential resection for initially unresectable HCC, and liver transplantation for small HCC. In nonsurgery, regional cancer therapy has been a new trend, which includes transcatheter arterial chemoembolization, percutaneous ethanol injection for small HCC, and others. As a result of multimodality combination treatment and changing concepts in surgical oncology, the role of surgery in the treatment of HCC has become bigger. However, the inadequacy of regional cancer therapies, its multicentric origin and tumor invasiveness remain major targets to be studied for a curative treatment.
肝细胞癌(HCC)的治疗仍然是一个关键问题,在流行地区尤其如此。本文总结了最近4年的文献以及作者的数据。近几十年来,HCC的治疗取得了重大进展,这主要得益于医学影像学的进步、积极的手术方法、区域癌症治疗和多学科方法。能显著延长生存期的手术方法包括:切除(尤其是小肝癌切除)、对亚临床复发进行再次切除、减瘤手术以及对最初不可切除的HCC进行序贯切除,还有小肝癌的肝移植。在非手术治疗方面,区域癌症治疗已成为一种新趋势,包括经动脉化疗栓塞、对小肝癌进行经皮乙醇注射等。由于多模式联合治疗以及外科肿瘤学观念的转变,手术在HCC治疗中的作用变得更大。然而,区域癌症治疗的不足、其多中心起源和肿瘤侵袭性仍是寻求治愈性治疗需要研究的主要目标。